奥浦迈涨2.03%，成交额354.27万元

Group 1 - The core viewpoint of the news is that Aopumai's stock has shown significant performance with a year-to-date increase of 57.23%, despite a recent decline in the last five and twenty trading days [1] - Aopumai's main business involves cell culture products and services, with revenue composition being 87.34% from products and 12.53% from services [1] - As of September 30, 2025, Aopumai reported a revenue of 272 million yuan, representing a year-on-year growth of 25.79%, and a net profit attributable to shareholders of 49.43 million yuan, which is an increase of 81.48% compared to the previous year [1] Group 2 - Aopumai's stockholders increased to 3,682 as of September 30, 2025, marking a 14.63% rise from the previous period, with an average of 30,838 circulating shares per person, up by 27.96% [1] - The company has distributed a total of 173 million yuan in dividends since its A-share listing [1] - Among the top ten circulating shareholders, notable increases were observed in holdings by institutional investors, such as China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [2]